Autologous transplantation is controversial for older patients with multiple myeloma. The role of age-adjusted high-dose melphalan and the impact of preceeding induction chemotherapy cycles has been unclear.
High-dose chemotherapy with autologous blood stem-cell transplantation is considered the standard treatment for younger patients with multiple myeloma. 1, 2, 3 In older patients, however, its role is less clear and remains controversial. 4, 5, 6 As a consequence, many older but otherwise fit patients are excluded from the procedure. This may have contributed to a survival disadvantage. 7 Concerns about toxicity or an inferior outcome in comparison to younger patients continue to inhibit the application of high-dose therapy with autologous transplantation in older patients although its use has increased considerably in recent years. 8, 9 The available data are limited by the fact that these patients are underrepresented or missing entirely in the large recent prospective multicenter transplantation trials which mostly apply an age cutoff at 65 years. 10, 11, 12, 13, 14, 15, 16, 17 Limited information from higher age groups is based on retrospective single center experience mostly reporting limited numbers of patients 18, 19, 20, 21, 22, 23 or registry data lacking details of toxicity and outcome but demonstrating improvements in overall survival over the years. 8, 9 Melphalan 200 mg/m 2 (MEL200) represents the standard high-dose regimen for the younger patient population. 35 The frequent reluctance to apply MEL200 in patients above the age of 65 years is related to reasonable concerns of a potentially higher toxicity. As an alternative to MEL200, an age-adjusted melphalan dose of 140 mg/m 2 (MEL140) 38 can be given in patients above the age of 60 years. The intention is to decrease severe mucositis and other toxicities and thereby to enable autologous transplantation in older patients who are not considered eligible for MEL200. Reports
show that this strategy has become part of clinical routine today. 21, 23, 18, 20, 9 The proportion of patients receiving an age-adjustment of the melphalan dose is steadily increasing within the higher age groups when considering patients above the age of 60, above 65 and above 70 years. 9 randomized clinical trials investigated intermediate-dose melphalan (MEL100) with autologous transplantation in older patients. 24, 5 Data from a prospective randomized trial specifically reporting the efficacy and toxicity of MEL140 in the older patients has been lacking. Our study provides this missing information.
Historically, stem cell therapy is preceded by 3-6 cycles of induction chemotherapy. This strategy is regarded as important but since the progression-free survival achieved after autologous transplantation is a function of the complete treatment, the contribution of induction chemotherapy alone has remained undefined. In the prospective phase III trial presented here, we addressed [1] the role of conventional induction chemotherapy cycles prior to high-dose chemotherapy by randomization between anthracycline-based induction as representing the standard when the trial started and no induction cycles and [2] the real toxicity and efficacy of tandem MEL140 with and without induction chemotherapy in a large older age patient group.
Methods

Patients and Study Design
This randomized multicenter trial was planned by the German Multiple Myeloma Study Patients with no previous chemotherapy or a maximum of one cycle were randomly assigned between conventional induction chemotherapy cycles and a short course of dexamethasone only ( Figure 1A ). Novartis provided financial support for conducting the study, but was not involved in data collection, data analysis or writing the manuscript. Molecular cytogenetic analysis was supported by the Deutsche José Carreras Leukämie-Stiftung. The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the local ethics committees at each participating center. Patients were required to provide written informed consent before enrollment.
The study was registered under www.clinicaltrials.gov NCT02288741.
Treatment plan
In the arm with induction chemotherapy cycles, patients received 4 cycles of conventional anthracycline-dexamethasone-based regimens. Specified in the protocol were vincristine-doxorubicin-dexamethasone (VAD), 25 idarubicin-dexamethasone (ID) 26 and cyclophosphamide-doxorubicin-dexamethasone (CAD). 27 In the arm with no induction cycles, patients received only dexamethasone 40 mg orally on days 1-4 and 8-11 for symptom control. For the subsequent stem-cell mobilization, age-adjusted (75% dose) ifosfamide-epirubicin-etoposide (IEV) with G-CSF was recommended. 28 The target dose for stem cell collection was 6 x 10 6 CD34-positive cells/kg (two transplants and one back-up). The standard dose for each transplantation was 2 x 10 6 CD34-positive cells/kg. High-dose melphalan at a total dose of 140 mg/m 2 (MEL140) was given in two doses of 70 mg/m 2 on days -3 and -2. Stem cell transplantation was performed on day 0. A second MEL140 course was planned two months after the first.
No maintenance treatment was given but regular bisphosphonate administration was recommended.
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The primary study endpoint was progression-free survival calculated from the time point of randomization. To detect a 10-month advantage in progression-free survival for the arm with induction chemotherapy cycles (from 24 to 34 months, corresponding to a hazard ratio of 0.71) with a power of 80% and based on a one-sided type I error rate of 0.05, a number of at least 132 patients per randomization arm was required.
Toxicity of treatment was evaluated using Common Toxicity Criteria (version 2.0, 1999), the definition of remission followed the EBMT criteria. 29 Except for the primary endpoint, all analyses were descriptive or explorative in nature, providing two-sided p-values without referring to a specified error level. Adjustments for multiple testing were not performed. Proportions were eventually compared using Fisher's exact or chi² test. All time-to-event endpoints were calculated according to the method of Kaplan and Meier.
Survival curves were compared using the log rank test. Hazard ratios with confidence intervals were derived from Cox models.
Results
Patients
The study design and the consort diagram are shown in Figure 1 . A total of 434 patients were enrolled into the study protocol and were randomized. Fourteen patients (3%)
were excluded from analysis. Accordingly, 420 patients could be analysed with respect to the primary endpoint progression-free survival. The median follow-up period was 5.2 years (range 0-10.1 years) . The details of consecutive treatment steps were documented in 416 patients. The baseline characteristics of patients are shown in Table   1 .
Induction chemotherapy
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In the arm with induction chemotherapy cycles consisting of 207 patients, 98% of patients received one of the recommended induction regimens (idarubicindexamethasone 67%, vincristine-doxorubicin-dexamethasone 25%, cyclophosphamidedoxorubicin-dexamethasone 6%), with dexamethasone alone being used for 2%. A median of 4 cycles (range1-7 cycles) was given for a median of 3.9 months (range 0.3-
months).
In the arm with no induction cycles, the two times 4x40 mg dexamethasone were given for a median of 0.7 months (range 0-5.7 months) before stem cell mobilization started.
Stem-cell mobilization and autologous transplantation
A total of 385 patients (92%) were treated with stem cell mobilization chemotherapy using the ifosfamide-epirubicin-etoposide regimen in 89%, cyclophosphamidedoxorubicin-dexamethasone in 5%, cyclophosphamide in 4%, cyclophosphamideetoposide in 1% and ifosfamide in 1%. Stem-cell collections were carried out in 376
patients. The recommended target value (≥ 6 x 10 6 CD34 + cells/kg) and the required dose for a double transplantation (≥ 4 x 10 6 CD34 + cells/kg) was achieved in 80% and in 90%, respectively. Afterwards, 357 patients (85%) received at least one transplant and 289 patients (69%) completed a double transplant. The main reasons for drop-out in the 68 patients (16%) who did not receive the second transplant were progression of disease (21%), toxicity (22%), death (7%), refusal of the patient (18%) and insufficient stem cell collection (7%).
Toxicity, deaths and second primary malignancies
The major grade III/IV non-hematological toxicities were infection and mucositis (Table   2) . Deaths up to 100 days from the last treatment occurred in 25 patients (6.0%). in 5 patients (1.2%) progression of disease was the cause whereas toxicity (infection, 26 .07.2016 07:02
sepsis, renal failure, cardiac) played a role in 20 patients (4.8%). In 20 of 25 cases death occurred before the first MEL140. Transplant-related mortality was very low. It was 1.4% after the first MEL140 and very notably, 0% following the second MEL140.
Some grade III/IV mucositis was seen during induction chemotherapy cycles (4%), and was absent during the short dexamethasone pre-phase. The comparison of the two treatment arms showed 2% vs 6% grade III/IV mucositis after mobilization, 11% vs 16%
after the first MEL140 course and 5% vs 7% for the second MEL140, respectively.
Moderate rates of grade III/IV infections occurred during induction chemotherapy cycles or the dexamethasone pre-phase (17% vs 4%), after mobilization (17% vs 30%), and at a higher frequency after the first MEL140 (35% vs 44%) and second MEL140 (38% vs 34%). In 4 out of 420 patients (1%) a second primary malignancy was reported (two solid tumors, two acute myeloid leukemias).
Response rates
The response rates reflected treatment differences and treatment progress between patients in the two arms (Table3). There was an initial lag in response rate in the arm with no induction cycles. However, this recovered in the following treatment steps and after the second MEL140 the response rates were similar in the two arms.
Long term outcomes after randomization
The median progression-free survival for patients with induction chemotherapy cycles were seen beyond five years.
Treatment effects in age subgroups
The discontinuation rate before the first high-dose melphalan course was somewhat higher for the patients 65-70 years (18%) than for those aged 60-64 years (9%). The drop-out rate after the first MEL140 was similar for the younger (18%) and the older (17%) patients. More patients 60-64 years than 65-70 years completed tandem MEL140
(73% vs 65%). Deaths within 100 days from the last treatment were more frequent during the induction phase in patients 65-70 years (6.1% vs 3.1%), but were similar in both age groups following the first transplant (1.6% vs 1.1%) and did not occur in either age group after the second transplant. On the intention-to-treat basis, median progression-free survival in younger versus older patients (19.5 and 22.1 months;
P=0.23) and median overall survival (56.3 months and 53.1 months; P=0.58) were similar ( Figure 3A ). P<0.0001) ( Figure 3B ). The patients with low-risk cytogenetics who completed double transplantation (78%) had an excellent outcome (median progression-free survival 26.7 months and median overall survival 87.4 months). Patients still alive in sustained first remission beyond five years were seen in association with low-risk cytogenetics.
Discussion
Our trial abandoned induction chemotherapy cycles before autologous transplantation in one arm of the study in order to test the relationship between induction chemotherapy and autologous transplantation and did not use consolidation or maintenance therapy.
This must be considered when comparing the outcome of our trial to other trial results which have applied the common strategy of incorporating all available drugs into treatment phases before and after stem cell therapy striving for a maximum duration of progression-free survival after first-line treatment in multiple myeloma patients.
(Unexpectedly,) We found that the overwhelming part of the anti-tumor effect (96%) was achieved with high-dose chemotherapy and autologous transplantation alone and that the contribution of 4 cycles of anthracycline-based induction chemotherapy was small. By 3-4 months of anthracycline-based induction therapy, the progression-free survival was improved by only 2 months. Based on the hazard ratio of the two-arm comparison, such induction chemotherapy cycles achieved only 4% of the progression-free survival.
Anthracycline-based induction chemotherapy was the standard when our trial started but has been replaced by induction regimens incorporating novel agents. In this respect both arms of our trial may be regarded as a "baseline" from where the achievements of novel agent-based induction therapy can be judged. Currently used bortezomib-based induction regimens 13, 11, 32, 33, 34, 15 were found to increase the progression-free survival over the typical anthracycline-based regimen VAD 13, 15 by approximately 6 months.
Despite this improvement, the estimated impact of such induction therapy on the overall progression-free survival appears to be limited taking into account our "baseline" results and the results from other trials demonstrating a high efficacy of post-transplant treatments with novel agents 10, 12, 14 .
Our study is the first prospective randomized trial which has characterized the real toxicity and efficacy of MEL140 with autologous transplantation in older patients with multiple myeloma. ()The results highlight an independent role for autologous transplantation in older patients. The tolerability of MEL140 was favorable. The rate of severe mucositis was around 10%, transplant-related mortality around 1%. It should be emphasized that following the treatment pause after the first MEL140, the nonhematological toxicity of the second MEL140 appeared to be somewhat lower compared to the first MEL140 -at least not higher -and the transplant-related mortality was 0%. Importantly, , the long-term outcome shows the existence of a subgroup of patients who did not relapse after MEL140 over a number of years. This may indicate some curative potential with age-adjusted high-dose melphalan. For more than 200 patients aged 65-70 years, the outcome was at least as good compared to the younger patients in this study, demonstrating a lacking relevance of an age cut-off at 65 years for 26 .07.2016 07:02
MEL140. The long-term outcome for the tandem MEL140 component in conjunction with the large number of patients treated may serve as a point of reference for future trials. Geriatric assessment and comorbidity scores will be helpful to encourage autologous transplantation in many older patients with multiple myeloma. 45, 46 The low rate of second primary malignancies following tandem MEL140 in comparison to the published literature 47 is noteworthy and could be related to the limited first-line treatment in the study population.
Due to a significant effort of a central laboratory, we can present up-to-date cytogenetic data in around 200 patients. Many publications define high-risk versus standard-risk groups but very few reports indicate a low-risk group as defined by the IMWG 31, 30 . This requires investigation of 1q21 gains together with analysis of translocation (4;14) and deletion 17p. We found that the 50% of myeloma patients of this age group who had a low-risk cytogenetic profile showed an excellent survival with front-line age-adjusted high-dose melphalan. Importantly, the patients with low-risk cytogenetics inclosed those with sustained unmaintained first remission, some of them being possibly cured.
Recently, treatment with novel agents plus autologous transplantation was found to be more effective than novel agents plus conventional chemotherapy in patients up to 65 years of age. 14, 16, 17 The similarly needed randomized clinical trials in the older patient population may rely on tandem MEL140 as the backbone treatment.
Another important aspect to consider is that the concept of age-adjusted high-dose melphalan includes double transplantation, which compensates the single melphalan dose reduction. The tandem MEL100 regimen devided the standard MEL200 dose in two parts and enabled autologous transplantation of older patients at reduced toxicity. 24, 5, 40 A tandem application of MEL200 in older patients, however, was found to decrease steeply with higher age for obvious reasons. 22 In contrast, in our trial a speedy Such a comparison could be investigated in a prospective randomized trial for patients 60-70 years of age.
In fact, our trial shows that the treatment trunk consisting of stem-cell mobilization chemotherapy followed by tandem MEL140 with autologous transplantation despite its short treatment time of 4-5 months is powerful with a progression-free survival time of 20-23 months. Current non-transplant regimens used in this age group such as VMP 41 or MPT 42 or MPR 43 or Rd 44 provide a similar progression-free survival (median 22, 20, 14 and 21 months, respectively) but are associated with the development of neuropathy or thrombosis and thromboembolism and require a prolonged treatment time that does often exceed one year. The "aggressiveness" of age-adjusted high-dose therapy on the other hand is low and predictable as demonstrated by our trial. Older fit patients may therefore benefit from an age-adjusted transplant program that would allow longer unmaintained remissions following transplantation during which patients can enjoy freedom-from-therapy. When lenalidomide is continued as maintenance therapy in the MPRR 43 or continues Rd 44 regimens, the progression-free survival can be extended. In analogy, lenalidomide maintenance can also be used after MEL140. 10, 12, 14, 40 We do not discuss in detail preference for MEL140 or MEL200 for subgroups of older patients because this has been discussed extensively in many previous publications and was not investigated in this trial. The known arguments center around the specific features of MEL200 (higher toxicity, potentially higher efficacy, single transplantation, prospective randomized trials in specific age groups which, however, are completely lacking. Therefore MEL140 and MEL200 represent complementary rather than competing options for older patients today.
We conclude that tandem MEL140 with autologous stem-cell transplantation can be kept short with a long-lasting unmaintained remission to follow and qualifies as an independent component of myeloma therapy. A sustained first remission is associated with low-risk cytogenetics present in around 50% of patients.
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